Skip to main content
Erschienen in: Head and Neck Pathology 3/2022

07.03.2022 | Case Reports

SMARCB1 (INI1)-Deficient Sinonasal Carcinoma with Yolk Sac differentiation Showing Co-loss of SMARCA4 Immunostaining – A Case Report and Literature Review

verfasst von: Joanna K. M. Ng, Jason Y. K. Chan, Joshua J. X. Li, Kinglam Tang, David C. M. Yeung, Amy B. W. Chan

Erschienen in: Head and Neck Pathology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

SMARCB1 (INI1)-deficient carcinoma of the sinonasal tract is a rare and distinct entity characterized by the loss of INI1 immunostain expression. These tumors are morphologically diverse, with isolated cases of yolk sac differentiation reported. We report the first case of SMARCB1-deficient sinonasal carcinoma that demonstrated co-loss of SMARCA4 immunostain, and reduced SMARCA2 and ARID1A staining, with the entire tumor showing histological and immunohistochemical evidence of yolk sac differentiation. The clinical, histological, immunohistochemical and molecular features were discussed and compared against SMARCB1-deficient sinonasal carcinomas with yolk sac differentiation and SMARCA4-deficeint sinonasal carcinomas reported in the literature. With a highly aggressive clinical course leading to mortality two months after presentation, the behavior of this tumor appears to be more comparable to that of SMARCA4-deficient sinonasal carcinomas. A comprehensive immunopanel including SMARCB1, SMARCA4, SMARCA2 and ARID1A may be advisable for assessment and prognostication of SWI/SNF-deficient tumors.
Literatur
1.
Zurück zum Zitat Bishop JA, Antonescu CR, Westra WH. SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. Am J Surg Pathol. 2014;38(9):1282–9.CrossRef Bishop JA, Antonescu CR, Westra WH. SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. Am J Surg Pathol. 2014;38(9):1282–9.CrossRef
2.
Zurück zum Zitat Agaimy A, Koch M, Lell M, Semrau S, Dudek W, Wachter DL, et al. SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms. Am J Surg Pathol. 2014;38(9):1274–81.CrossRef Agaimy A, Koch M, Lell M, Semrau S, Dudek W, Wachter DL, et al. SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms. Am J Surg Pathol. 2014;38(9):1274–81.CrossRef
3.
Zurück zum Zitat Shah AA, Jain D, Ababneh E, Agaimy A, Hoschar AP, Griffith CC, et al. SMARCB1 (INI-1)-Deficient Adenocarcinoma of the Sinonasal Tract: A Potentially Under-Recognized form of Sinonasal Adenocarcinoma with Occasional Yolk Sac Tumor-Like Features. Head Neck Pathol. 2020;14(2):465–72.CrossRef Shah AA, Jain D, Ababneh E, Agaimy A, Hoschar AP, Griffith CC, et al. SMARCB1 (INI-1)-Deficient Adenocarcinoma of the Sinonasal Tract: A Potentially Under-Recognized form of Sinonasal Adenocarcinoma with Occasional Yolk Sac Tumor-Like Features. Head Neck Pathol. 2020;14(2):465–72.CrossRef
4.
Zurück zum Zitat Agaimy A, Jain D, Uddin N, Rooper LM, Bishop JA. SMARCA4-deficient Sinonasal Carcinoma: A Series of 10 Cases Expanding the Genetic Spectrum of SWI/SNF-driven Sinonasal Malignancies. Am J Surg Pathol. 2020;44(5):703–10.CrossRef Agaimy A, Jain D, Uddin N, Rooper LM, Bishop JA. SMARCA4-deficient Sinonasal Carcinoma: A Series of 10 Cases Expanding the Genetic Spectrum of SWI/SNF-driven Sinonasal Malignancies. Am J Surg Pathol. 2020;44(5):703–10.CrossRef
5.
Zurück zum Zitat Zamecnik M, Rychnovsky J, Syrovatka J. Sinonasal SMARCB1 (INI1) Deficient Carcinoma With Yolk Sac Tumor Differentiation: Report of a Case and Comparison With INI1 Expression in Gonadal Germ Cell Tumors. Int J Surg Pathol. 2018;26(3):245–9.CrossRef Zamecnik M, Rychnovsky J, Syrovatka J. Sinonasal SMARCB1 (INI1) Deficient Carcinoma With Yolk Sac Tumor Differentiation: Report of a Case and Comparison With INI1 Expression in Gonadal Germ Cell Tumors. Int J Surg Pathol. 2018;26(3):245–9.CrossRef
6.
Zurück zum Zitat Gallo A, Fankhauser C, Hermanns T, Beyer J, Christiansen A, Moch H, et al. HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors. Mod Pathol. 2020;33(11):2354–60.CrossRef Gallo A, Fankhauser C, Hermanns T, Beyer J, Christiansen A, Moch H, et al. HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors. Mod Pathol. 2020;33(11):2354–60.CrossRef
7.
Zurück zum Zitat Bing Z, Pasha T, Tomaszewski JE, Zhang P. CDX2 expression in yolk sac component of testicular germ cell tumors. Int J Surg Pathol. 2009;17(5):373–7.CrossRef Bing Z, Pasha T, Tomaszewski JE, Zhang P. CDX2 expression in yolk sac component of testicular germ cell tumors. Int J Surg Pathol. 2009;17(5):373–7.CrossRef
8.
Zurück zum Zitat Masliah-Planchon J, Bièche I, Guinebretière JM, Bourdeaut F, Delattre O. SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol. 2015;10:145–71.CrossRef Masliah-Planchon J, Bièche I, Guinebretière JM, Bourdeaut F, Delattre O. SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol. 2015;10:145–71.CrossRef
9.
Zurück zum Zitat Schallenberg S, Bork J, Essakly A, Alakus H, Buettner R, Hillmer AM, et al. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma. BMC Cancer. 2020;20(1):12.CrossRef Schallenberg S, Bork J, Essakly A, Alakus H, Buettner R, Hillmer AM, et al. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma. BMC Cancer. 2020;20(1):12.CrossRef
10.
Zurück zum Zitat Karnezis AN, Hoang LN, Coatham M, Ravn S, Almadani N, Tessier-Cloutier B, et al. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol. 2016;29(3):302–14.CrossRef Karnezis AN, Hoang LN, Coatham M, Ravn S, Almadani N, Tessier-Cloutier B, et al. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol. 2016;29(3):302–14.CrossRef
11.
Zurück zum Zitat El-Naggar, AKCJKCRGJTTSPJIAfRoC. WHO classification of head and neck tumours2017. El-Naggar, AKCJKCRGJTTSPJIAfRoC. WHO classification of head and neck tumours2017.
12.
Zurück zum Zitat Agaimy A, Hartmann A, Antonescu CR, Chiosea SI, El-Mofty SK, Geddert H, et al. SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity. Am J Surg Pathol. 2017;41(4):458–71.CrossRef Agaimy A, Hartmann A, Antonescu CR, Chiosea SI, El-Mofty SK, Geddert H, et al. SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity. Am J Surg Pathol. 2017;41(4):458–71.CrossRef
13.
Zurück zum Zitat Li CY, Han YM, Xu K, Wu SY, Lin XY, Cao HY. Case Report: SMARCB1 (INI-1)-Deficient Carcinoma of the Nasal Cavity with Pure Yolk Sac Tumor Differentiation and Elevated Serum AFP Levels. Onco Targets Ther. 2021;14:2227–33.CrossRef Li CY, Han YM, Xu K, Wu SY, Lin XY, Cao HY. Case Report: SMARCB1 (INI-1)-Deficient Carcinoma of the Nasal Cavity with Pure Yolk Sac Tumor Differentiation and Elevated Serum AFP Levels. Onco Targets Ther. 2021;14:2227–33.CrossRef
14.
Zurück zum Zitat Hazir B, Şímșek B, Erdemír A, Gürler F, Yazici O, Kizil Y, et al. Sinonasal SMARCB1 (INI1) Deficient Carcinoma with Yolk Sac Tumor Differentiation: A Case Report and Treatment Options. Head Neck Pathol; 2021. Hazir B, Şímșek B, Erdemír A, Gürler F, Yazici O, Kizil Y, et al. Sinonasal SMARCB1 (INI1) Deficient Carcinoma with Yolk Sac Tumor Differentiation: A Case Report and Treatment Options. Head Neck Pathol; 2021.
15.
Zurück zum Zitat Agaimy A, Daum O, Märkl B, Lichtmannegger I, Michal M, Hartmann A. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2. Am J Surg Pathol. 2016;40(4):544–53.CrossRef Agaimy A, Daum O, Märkl B, Lichtmannegger I, Michal M, Hartmann A. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2. Am J Surg Pathol. 2016;40(4):544–53.CrossRef
Metadaten
Titel
SMARCB1 (INI1)-Deficient Sinonasal Carcinoma with Yolk Sac differentiation Showing Co-loss of SMARCA4 Immunostaining – A Case Report and Literature Review
verfasst von
Joanna K. M. Ng
Jason Y. K. Chan
Joshua J. X. Li
Kinglam Tang
David C. M. Yeung
Amy B. W. Chan
Publikationsdatum
07.03.2022
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 3/2022
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-022-01423-y

Weitere Artikel der Ausgabe 3/2022

Head and Neck Pathology 3/2022 Zur Ausgabe

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Thiopental Originalie

Als Folge des Urteils des Bundesverfassungsgerichts zur Sterbehilfe im Jahr 2020 wurde in den Jahren 2021–2023 eine Reihe (n = 23) von assistierten Suiziden im Landesinstitut für gerichtliche und soziale Medizin Berlin mit jeweils identischen …

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …